Video Series

Payer considerations for evaluating treatment costs in schizophrenia care are addressed by Caroline P. Carney, MD, MSc, FAPA, FAPM, CPHQ.

The panel highlights the current standards of care and strategies for treating children with RSV.

Long-term effects of pediatric RSV diagnosis are explored.

A look at the most common medications used in patients with acne.

The panel speaks to how to treat acne for people who are pregnant and/or lactating.

An overview of data presented at ESMO GI 2023 on combined botensilimab and balstilimab therapy in heavily pretreated patients with microsatellite stable metastatic colorectal cancer.

Navigating the efficacy of schizophrenia treatment selection.

The use of cognitive behavioral therapy (CBT) in schizophrenia treatment is examined.

Medical experts discuss current obstacles facing ideal respiratory syncytial virus (RSV) treatment strategies in children.

A look at the psychological implications of acne in teenagers and adults.

Discussion on the economic burden of over-counter and prescription drug costs related to acne therapy.

Dr Marshall describes the impacts of microsatellite stability and instability on metastatic colorectal cancer.

Dr Carney drives a discussion surrounding optimal treatment strategies for schizophrenia.

Panelists provide insight into the standards of care for treating patients diagnosed with schizophrenia.

A panel of experts discuss future opportunities with interchangeable biosimilars from payer and provider perspectives.

Jonathan Kay, MD, and Kimberly C. Chen, DO, MSHLM, discuss clinical and financial concerns related to automatic substitution at the pharmacy for an interchangeable biosimilar from a payer perspective.

Conversation on the four classic causes of acne as well as pathogenesis.

Introduction of expert panelists and treatment guidelines for patients with acne.

Discussion on shared decision making with patients with later stage refractory metastatic colorectal cancer as well as maximizing a patient's quality of life.

Maia Kayal, MD, MS, and Kimberly C. Chen, DO, MSHLM, discuss challenges for biosimilars with interchangeable designation related to automatic substitution in the pharmacy.

Kimberly C. Chen, DO, MSHLM, discusses the potential benefits of interchangeable biosimilars to patients and payers.

John L. Marshall M.D., shares insights on health-related quality of life (HRQoL) findings from SUNLIGHT study presented at ESMO World Congress on Gastrointestinal Cancer (ESMO GI) 2023.

A panel of medical experts discuss the clinical and financial considerations surrounding the treatment of patients diagnosed with schizophrenia.

Social determinants of health impacting the treatment landscape for schizophrenia are discussed.

A panel of experts reviews the emerging interchangeable biosimilars and best practices on how to educate providers and patients on these treatment options.

Maia Kayal, MD, MS, and Jonathan Kay, MD, define interchangeability and review the details of a switching study.

Carlos Larrauri, APRN, details the signs and symptoms necessary to make a schizophrenia diagnosis.

John J. Miller, MD, and Nev Jones, PhD, open a discussion providing an overview on the current state of patients with schizophrenia.